GRI

Business Context and Reporting Period

Company: GRI Bio, Inc. (GRI Bio)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: GRI Bio is a clinical-stage biopharmaceutical company developing therapies for inflammatory, fibrotic, and autoimmune disorders. Its lead product candidate, GRI-0621, is an oral inhibitor of type 1 invariant Natural Killer T (iNKT) cells being developed for Idiopathic Pulmonary Fibrosis (IPF). A second candidate, GRI-0803, is an oral agonist of type 2 diverse Natural Killer T (dNKT) cells being developed for Systemic Lupus Erythematosus (SLE). The company has no approved products and has never been profitable.

Key Financial Metrics

Note: All figures in millions unless otherwise noted. The company reported no revenue for either period.

Material Changes vs. Prior Period

• Reduced Net Loss: Net loss decreased by approximately $4.8 million (37%) from 2023 to 2024, primarily driven by a significant reduction in General and Administrative expenses.
• G&A Expense Reduction: G&A expenses dropped $3.7 million, attributed to decreased accounting, legal, and investment banking fees following the 2023 merger and reduced costs associated with being a public company.
• R&D Increase: R&D expenses increased by $0.6 million, reflecting continued investment in the GRI-0621 registration development program.
• Financing Activity: The company raised substantial capital in 2024 through multiple equity offerings, including a February 2024 offering, a June 2024 offering, and an At-The-Market (ATM) facility, resulting in a net increase in cash of $3.2 million for the year.
• Reverse Stock Splits: The company executed multiple reverse stock splits in 2024 (January and June) and a subsequent one in February 2025 to maintain Nasdaq listing compliance.

Guidance, Outlook, Risks, and Unusual Items

Outlook and Guidance

• Cash Runway: Management believes existing cash ($5.0 million as of Dec 31, 2024) is sufficient to fund operations only into the second quarter of 2025.
• Capital Needs: The company explicitly states it requires substantial additional capital to continue operations and clinical trials. Failure to secure funding could force delays, reductions, or elimination of development programs.
• Clinical Milestones: Topline results for the Phase 2a trial of GRI-0621 in IPF are expected in the third quarter of 2025. An IND for GRI-0803 (SLE) is expected to be filed in 2025.

Risks and Contingencies

• Going Concern: Independent auditors have expressed substantial doubt about the company's ability to continue as a going concern due to recurring losses and the need for additional financing.
• Internal Control Material Weakness: Management identified a material weakness in internal controls over financial reporting related to the inaccurate computation of a non-cash deemed dividend associated with the October 2024 Warrant Repricing Transaction. This was corrected prior to finalization of the report.
• Nasdaq Compliance: The company previously failed to meet the Minimum Bid Price Rule ($1.00) but regained compliance in March 2025 following a 1-for-17 reverse stock split. Continued compliance is not guaranteed.
• Enrollment Delays: The Phase 2a trial for GRI-0621 experienced enrollment delays, pushing topline data expectations from late 2024 to Q3 2025.

Unusual Items

• Warrant Repricing Transaction (Oct 2024): The company repriced Series B Common Warrants, offering holders a reduced exercise price and issuing new Series D warrants. This resulted in a $1.9 million deemed dividend recorded as a reduction in net loss available to common stockholders.

Key Facts for Investor Verification

• Liquidity Status: Verify the company's ability to raise capital before Q2 2025, as current cash reserves are insufficient for long-term operations.
• Clinical Trial Progress: Monitor enrollment rates and safety data for the GRI-0621 Phase 2a IPF trial, with topline data due Q3 2025.
• Internal Controls: Confirm the remediation plan for the material weakness regarding the warrant dividend calculation is effective.
• Stock Liquidity: Assess the impact of recent reverse stock splits on trading volume and liquidity of the common stock.
• Regulatory Pathway: Verify the FDA's acceptance of the Section 505(b)(2) regulatory pathway for GRI-0621, which relies on data from the previously approved topical formulation of tazarotene.